The COVID-19 epidemic (Coronavirus Disease 2019) currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). Epidemiologically, acute myeloblastic leukemias (AML) are the most common of acute leukemias. The incidence of acute lymphoblastic leukemia (ALL) is 900 new cases in France in 2018, of which 57% in humans. The treatments administered to AML and ALL patients induce variable immunosuppression: neutropenia, neuropathy, deficits in humoral or cellular immunity or combinations of these deficits. Patients with AML or ALL therefore represent a population at high risk of developing a serious form in the event of infection with SARS-CoV-2. To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in the population of patients with acute leukemia. The main objective of the study is to determine the clinical and biological prognostic factors during SARS-CoV-2 infection in patients with acute leukemia.
Inclusion Criteria:
- Diagnosis of acute leukemia according to WHO criteria 2016 ≤ 5 years
- Diagnosis of a proven or probable SARS-CoV-2 infection according to the following
criteria:
1. Proven infection: positive Polymerase Chain Reaction (PCR) regardless of the
radio-clinical picture (other tests made available later and having good
diagnostic performance will be accepted)
2. Probable infection: negative PCR but association of
1. Evocative clinical signs, of recent installation: fever, respiratory signs
(cough, dyspnea, chest pain), body aches, sore throat, rhinorrhea, headache,
diarrhea / abdominal pain, frank asthenia, loss of taste / smell,
conjunctivitis, type of frostbite AND
2. evocative radiological signs, on CT: diffuse or diffuse aspect of frosted
glass, condensations including pseudo-nodular condensations, association of
frosted glass and condensation within the same lesion, nodules and
micronodules, thickening of the interlobular septa) or on chest radiography:
interstitial, alveolo-interstitial or alveolar syndrome, single or bilateral
AND
3. absence of differential diagnosis
Exclusion Criteria:
- None
Chu Amiens
Amiens, France
CHU ANGERS - Maladies du sang
Angers, France
Ch Avignon
Avignon, France
CH de la Côte Basque - Hématologie
Bayonne, France
CHU Caen - IHBN - Hématologie Clinique
Caen, France
Centre Hospitalier Sud Francilien
Corbeil-essonnes, France
Centre Hospitalier de Dunkerque
Dunkerque, France
CHU de Grenoble - Hopital Michallon
Grenoble, France
Centre Hospitalier du Mans
Le Mans, France
Hôpital Saint Vicent de Paul
Lille, France
Chu Limoges
Limoges, France
Institut Paoli-Calmettes - Hématologie 2
Marseille, France
HOPITAL SAINT ELOI - Hematologie
Montpellier, France
HOPITAL E. MULLER - Hématologie
Mulhouse, France
CHU HOTEL DIEU - Hématologie Clinique
Nantes, France
CHU Caremeau
Nîmes, France
CENTRE HOSPITALIER SAINTJEAN - Hématologie Clinique
Perpignan, France
Bordeaux Pessac
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
CHU Reims - Hôpital Robert Debré - Hématologie Clinique
Reims, France
CHU Pontchaillou - Hématologie
Rennes, France
Chu de La Reunion - Site Sud
Saint-pierre, France
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, France
Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie
Toulouse, France
CHU de Brabois
Vandœuvre-lès-Nancy, France
Centre Hospitalier de Versailles
Versailles, France
Institut Gustave Roussy
Villejuif, France
Pierre-Yves DUMAS, Dr, Principal Investigator
French Innovative Leukemia Organisation